2D/3D Cell Cultures, Soft Tissue Sarcoma, Xenograft Model
Conditions
Brief summary
Outside the setting of well-designed prospective clinical studies, the current standard preoperative RT should be a conventionally 1.8-2 Gy fractionated regimen to a total dose of 50 Gy in 5-6 weeks. However, given the vast diversity of sarcoma subtypes, it is also unlikely to assume a uniform therapeutic management to be optimal for all sarcomas alike. Other than 2 Gy fraction sizes and/or 50 Gy total dose series have been investigated in the past and should be further exploited in the future, but the practical implementation in humans is hampered by the rarity of the disease. The current systemic treatment of sarcomas consists of both the older cytotoxic chemotherapies and the newer targeted therapies like tyrosine kinase inhibitors. But it is hard to predict which patients will respond to which specific systemic treatment. This leads to worse prognoses and unnecessary toxicity for sarcoma patients. Despite the fact that the number of sarcoma patients in current studies is too small with a mix of different subtypes, some subtypes show a better response than other subtypes. This platform may form the basis for preclinical translational investigations with radiotherapy and various systemic treatments.
Interventions
OTHERtumor biopsy
biopsy
Sponsors
KU Leuven
The Netherlands Cancer Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed diagnosed (non-) metastatic intermediate to high grade STS * Local recurrences are allowed * Age ≥ 18 years * Able and willing to undergo tumour biopsies or tumour sampling during surgery * Localization of sarcoma enables safe biopsy or surgery * Written informed consent
Exclusion criteria
* Known coagulation disorder and/or anticoagulant medication in as far it might interfere with a safe biopsy procedure (to the discretion of the treating physician and attending radiologist) * Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| A model for translational research | 2 years after start of study | take rate |
| The take-rate of fresh human PDX tumour material in nude mice. | 4 months | take rate |
| A consistent system for further anti-sarcoma therapy (both RT and chemotherapy experiments) | 2 years after start of study | take rate |
| A platform of 2D/3D cell cultures (organoids) of Soft Tissue Sarcomas. | 6 weeks | take rate |
| A platform of Patient Derived Xenografts (PDX) of Soft Tissue Sarcomas of patients with sarcomas | 4 months | take rate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fractionation sensitivity on several STS subtypes in PDX. | 4 months | take rate |
| To study the passage possibilities of 2D/3D cell cultures by freezing, storing and thawing | 1 month | take rate of continuous growth |
| The passage possibilities of human PDX tumour material by freezing, storing, thawing and re-inoculating in nude mice | 4 months after implantation of tumour material | take rate of continuous growth of implantation of tumor material |
Countries
Netherlands
Contacts
Primary ContactRick Haas, MD, PhD
Backup ContactAstrid Scholten, MD, PhD
Outcome results
None listed